Nelarabine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Nelarabine: From T-Cell Leukemia/Lymphoma to Relapsing-Remitting Multiple Sclerosis
One-Sentence Summary
Nelarabine is a purine nucleoside analog cytotoxic drug. It is generally used for T-cell hematologic malignancies, but the US regulatory data provided does not list an approved indication. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis, but 0 clinical trials and 0 publications currently support this direction. This is a model-only prediction with a serious neurotoxicity concern.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the provided data (all license records have empty indication text). Nelarabine is generally known as a T-cell leukemia/lymphoma agent. |
| Predicted New Indication | Relapsing-remitting multiple sclerosis |
| TxGNN Prediction Score | 99.43% (rank 13,256) |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 15 (NDA and ANDA licenses combined) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Based on general pharmacology, nelarabine is a prodrug of ara-G, a purine nucleoside analog that is preferentially cytotoxic to T-lymphocytes. This link comes from general knowledge, not from the input data.
The proposed connection to relapsing-remitting MS is T-cell depletion. Autoreactive T-cells are thought to drive MS, and cladribine, another purine analog, is already used in relapsing MS. A T-cell-selective agent could conceptually act in a similar way.
This rationale is plausible but unverified. Nelarabine is known to carry a boxed warning for severe neurotoxicity, including demyelination, peripheral neuropathy and Guillain-Barré-like ascending paralysis. Such toxicity is a serious liability in a demyelinating CNS disease. Without clinical data, the risk-benefit balance cannot be assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The record lists 15 licenses in total. The five main ones are shown below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021877 | Arranon (Sandoz Inc) | Injection | Not provided in source data |
| ANDA216038 | Nelarabine (Meitheal Pharmaceuticals Inc) | Injection | Not provided in source data |
| ANDA215037 | Nelarabine (Zydus Lifesciences Limited) | Injection | Not provided in source data |
| ANDA216934 | Nelarabine (Dr. Reddy’s Laboratories, Inc.) | Injection | Not provided in source data |
| ANDA212605 | Nelarabine (Gland Pharma Limited) | Injection | Not provided in source data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analog, prodrug of ara-G) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions. Neurologic assessment is essential given the neurotoxicity concern. |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Key Warnings: The source data has no warning entries. From general pharmacology, nelarabine carries a boxed warning for severe neurotoxicity (demyelination, peripheral neuropathy, Guillain-Barré-like ascending paralysis). This should be verified against the current package insert.
- Drug Interactions: No interaction records were found in the queried source (0 entries).
Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (L5), with no supporting trials or literature. The known neurotoxicity, including demyelination, directly conflicts with the target disease, so the risk-benefit balance is unfavorable without clinical data.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the US licenses
- A literature and trial search on purine analogs in MS, and on nelarabine neurotoxicity mechanisms
- Preclinical evidence that a T-cell-depleting effect can be achieved without CNS demyelination risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.